Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia
Khamis et al.
, Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in..
, International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.008
Small 89 patient RCT comparing favipiravir and inhaled interferon with HCQ for moderate to severe COVID-19 pneumonia, not finding significant differences. There was no control group.
This study is excluded in the after exclusion results of meta
study compares against another treatment showing significant efficacy.
risk of death, 14.8% lower, RR 0.85, p = 1.00, treatment 5 of 44 (11.4%), control 6 of 45 (13.3%), NNT 51.
risk of ICU admission, 2.3% higher, RR 1.02, p = 1.00, treatment 8 of 44 (18.2%), control 8 of 45 (17.8%).
risk of no recovery, 9.6% higher, RR 1.10, p = 0.82, treatment 15 of 44 (34.1%), control 14 of 45 (31.1%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Khamis et al., 9 Nov 2020, Randomized Controlled Trial, Oman, peer-reviewed, 11 authors, study period 22 June, 2020 - 13 August, 2020, this trial compares with another treatment - results may be better when compared to placebo, this trial uses multiple treatments in the treatment arm (combined with interferon beta-1b) - results of individual treatments may vary.
Abstract: International Journal of Infectious Diseases 102 (2021) 538–543
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
journal homepage: www.elsevier.com/locate/ijid
Randomized controlled open label trial on the use of favipiravir
combined with inhaled interferon beta-1b in hospitalized patients
with moderate to severe COVID-19 pneumonia
Faryal Khamisa,* , Hanan Al Naabib , Adil Al Lawatib , Zaiyana Ambusaidib ,
Mariam Al Sharjic, Umkulthum Al Barwanid , Nenad Pandaka , Zakariya Al Balushia ,
Maher Al Bahranie , Issa Al Salmif , Ibrahim Al-Zakwanig
Infection Diseases Unit, Department of Medicine, Royal Hospital, Muscat, Oman
Acute Medicine Unit, Department of Medicine, Royal Hospital, Muscat, Oman
Department of Nursing, Royal Hospital, Muscat, Oman
Department of Pharmacy, Royal Hospital, Muscat, Oman
Department of Anesthesia and Critical Care, Royal Hospital, Muscat, Oman
Department of Nephrology, Royal Hospital, Muscat, Oman
Department of Pharmacology & Clinical Pharmacy, College of Medicine & Clinical Pharmacy, Sultan Qaboos University, Muscat, Oman
A R T I C L E I N F O
A B S T R A C T
Received 21 September 2020
Received in revised form 3 November 2020
Accepted 4 November 2020
Objective: To evaluate the therapeutic effectiveness of favipiravir combined with inhaled interferon beta1b in adult patients hospitalized with moderate to severe COVID-19 pneumonia.
Methods: A randomized, open-label controlled trial of oral favipiravir in adults hospitalized with
moderate to severe COVID-19 pneumonia from June 22nd 2020 to August 13th 2020 was conducted.
Patients were randomly assigned to receive either a combination of favipiravir with interferon beta-1b by
inhalation aerosol or hydroxychloroquine (HCQ). The outcome endpoints included improvement in
inﬂammatory markers, lower length of hospital stay (LOS), discharges and lower overall 14-day mortality.
Results: A total of 89 patients underwent randomization with 49% (n = 44) assigned to favipiravir and 51%
(n = 45) assigned HCQ. The overall mean age was 55 14 years and 58% (n = 52) were males. There were
no signiﬁcant differences in the inﬂammatory biomarkers at hospital discharge between the two groups;
C-reactive protein (p = 0.413), ferritin (p = 0.968), lactate dehydrogenase (p = 0.259) and interleukin 6 (p =
0.410). There were also no signiﬁcant differences between the two groups with regards to the overall LOS
(7 vs 7 days; p = 0.948), transfers to the ICU (18.2% vs 17.8%; p = 0.960), discharges (65.9% vs 68.9%; p =
0.764) and overall mortality (11.4% vs 13.3%; p = 0.778).
Conclusions: No differences in clinical outcomes were found between favipiravir plus inhaled interferon
beta-1b and hydroxychloroquine in adults hospitalized with moderate to severe COVID-19 pneumonia.
© 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-ncnd/4.0/).
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.